Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine

References

• Huh WK, Joura EA, Giuliano AR, Iversen O-E, Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi E, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomized, double-blind trial. Lancet. 2017;390(10108): 2143–2159.doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8): 711–723.doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Roberts C, Green T, Hess E, Matys K, Brown MJ, Haupt RM, Luxembourg A, Vuocolo S, Saah A, Antonello J. Development of a human papillomavirus competitive immunoassay for nine HPV types. Hum Vaccines Immunother. 2014;10(8):2168–2174. doi:10.4161/hv.29205.
   PubMed Web of Science ®Google Scholar
• Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, Saah A. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vacc Immunol. 2012;19(6):881–885. doi:10.1128/CVI.00002-12.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814. doi:10.1086/597071.
   PubMed Web of Science ®Google Scholar
• Dickens P, Srivastava G, Loke SL, Larkin S. Human papillomavirus 6 and 11 in laryngeal papillomas. J Pathol. 1991;165(3):243–246. doi:10.1002/path.1711650308.
   PubMed Web of Science ®Google Scholar
• Forman D, De Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(suppl 5): F12–23.doi:10.1016/j.vaccine.2012.07.055.
   PubMed Web of Science ®Google Scholar
• Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, Souza CA, Marchiori E. Recurrent respiratory papillomatosis: A state-of-the-art review. Respir Med. 2017;126:116–121. doi:10.1016/j.rmed.2017.03.030.
   PubMed Web of Science ®Google Scholar
• Carifi M, Napolitano D, Morandi M, Dall’Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. 2015;11:731–738. doi:10.2147/TCRM.S81825.
   PubMed Web of Science ®Google Scholar
• Reeves WC, Ruparelia SS, Swanson KI, Derkay CS, Marcus A, Unger ER. National registry for juvenile onset recurrent respiratory papillomatosis. Arch Otolaryngologye Head Neck Surg. 2003;129(9):976–982. doi:10.1001/archotol.129.9.976.
   PubMedGoogle Scholar
• Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5): 271–278.doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19): 1928–1943.doi:10.1056/NEJMoa061760.
   PubMed Web of Science ®Google Scholar
• Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of Real-world experience. Clin Infect Dis. 2016;63(4): 519–527.doi:10.1056/NEJMoa061760.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, Skinner R, Liu B, Cornall AM, Kaldor JM, et al. Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 25 year old Australian women, nine years following implementation of vaccination. J Infect Dis. 2018;217(10): 1590–1600.doi:10.1093/infdis/jiy075.
   PubMed Web of Science ®Google Scholar
• Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, Harrison H, Black R, Perry C, Vijayasekaran S, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2): 208–212.doi:10.1093/infdis/jix498.
   PubMed Web of Science ®Google Scholar
• Chu H, Steinhoff C, Margaret A, Zaman K, Roy E, Langdon G, Formica MA, Walsh EE, Englund JA. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother –infant pairs in Bangladesh. J Infect Dis. 2014;210(10):1582–1589. doi:10.1093/infdis/jiu316.
   PubMed Web of Science ®Google Scholar
• Gupta A, Mathad J, Yang WT, Singh HK, Gupte N, Mave V, Bharadwaj R, Zaman K, Roy E, Bollinger RC, et al. Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs. Vaccine. 2014;32(13): 1466–1472.doi:10.1016/j.vaccine.2014.01.033.
   PubMed Web of Science ®Google Scholar
• Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynekf H, Pless R, Lambachh P, Zuber P. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014;32(52): 7057–7064.doi:10.1016/j.vaccine.2014.09.052.
   PubMed Web of Science ®Google Scholar
• Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, et al. Quadrivalent human papillomavirus vaccine phase III Investigators. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114(6): 1179–1188.doi:10.1097/AOG.0b013e3181c2ca21.
   PubMed Web of Science ®Google Scholar
• Moreira EDJ, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138:e 20154387. doi:10.1542/peds.2015-4387.
   Web of Science ®Google Scholar
• Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent hu-man papillomavirus vaccine. Vaccine. 2015;33(29):3422–3428. doi:10.1016/j.vaccine.2015.04.014.
   PubMed Web of Science ®Google Scholar
• Scheller NM, Pasternak B, Molgaard-Nielsen D, Svanström H, Hviid A. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med. 2017;376(13):1223–1233. doi:10.1056/NEJMoa1612296.
   PubMed Web of Science ®Google Scholar
• Lipkind HS, Vazquez-Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, Hechter RC, Jackson ML, Hambidge SJ, Lee GM, et al. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstet Gynecol. 2017;130(3): 599–608.doi:10.1097/AOG.0000000000002191.
   PubMed Web of Science ®Google Scholar
• Sy LS, Meyer KI, Klein NP, Chao C, Velicer C, Cheetham TC, Ackerson BK, Slezak JM, Takhar HS, Hansen J, et al. Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine. Hum Vaccin Immunother. 2018;14(2):412–419. doi:10.1080/21645515.2017.1403702.
   PubMed Web of Science ®Google Scholar
• Nygard M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol. 2015 Aug;22(8):943–948. doi:10.1128/CVI.00133-15.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2018;66(3): 339–345.doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Ferris D, Samakoses R, Block S, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen O-E, Joshi A, Chu JL, et al. Quadrivalent human papillomavirus vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140(6): pii:e20163947.doi:10.1542/peds.2016-3947.
   PubMed Web of Science ®Google Scholar